AngioDynamics (ANGO) stock

Medical devices , market cap $519M

Medical devices

Market cap $519M

$12.33

+5.12%

As of 9:51 AM ET, delayed 15+ min · Live for Pro members

Quality Score

-1

Poor

In its industry

#73of 85

Medical Devices

Checks firing

1of 14

Trending up

From 52-week high

-24.3%

Below the 200-day

Down:Down to Poor for the first time since Feb 2026. Scores before Sep 10, 2026 were rebuilt.

ANGO's Quality Score rose 1 point on Wed, Nov 4, to -1.

See ANGO's 14 chart checksSee it live, free for 24 hours. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Why is ANGO down?

Up 5.1% today with medical device stocks: LivaNova rose 16.9% after its report; 81 of 85 are up, 5.3% on average; the S&P 500 is up 1.7%; energy and AI power stocks fell.

Fell on Oct 8

Down 21% on Oct 8, and still 17% under its Oct 7 close.

“AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability.”

Its release that day said

Sources: Price history, Oct 8, 2026; Company release (8-K), Oct 8, 2026

1 more reason, free with an account →1 more reason why ANGO fell on Oct 8, from its filings, with the timeline and its peers, for Pro members.

Key facts on ANGO

Key facts on ANGO
Holding it back	A $33M loss wider than $32M a year earlier
Its score	Down:Down to Poor for the first time since Feb 2026 Scores before Sep 10, 2026 were rebuilt.
Latest filing	8-K, Oct 8 Reported its quarterly results

1 more reason behind ANGO's -1, free with an account →2 more reasons behind ANGO's -1, for Pro members.

ANGO in the news

TodayWith its group.

What's next

Mon Nov 9: UBS Global Healthcare Conference 2026Investor conference · date confirmed.

2 more dates ahead: the conference and the meeting, for Pro members.

ANGO catalysts

Coming up

After its last 4 reports it closed -11.6% on average, higher 1 of 4 times.

Why ANGO scores -1

Poorfor quality, not price, 1 of 14 chart checks firingWhat the Quality Score means

Well below its recent run. ANGO scores -1 today, against a median of 3 over its last 20 recorded sessions.

+1Chart checks 1 of 14 firing right now, one point each
−1Long-term trend below a falling 200-⁠day average

Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Growth addsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.
Insider trades subtracts

No effect today: Run-up, Size, Dilution, Volatility, Cash flow, Persistence, and News.

What every line is worth, and the reason behind it, on ANGO and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 9:51 AM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-⁠scored stocks returned 2.2x the average stock over the next month. How we tested it

Alert me when ANGO's Quality Score turns up

See it live, free for 24 hours. No account. No card. Then keep going with a free account.

Here is what Pro members see.

The same page for Pro members, on AMD
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on ANGO and every other stock.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

ANGO has 1 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on ANGO, and all 14 on every stock.Get in free →

ANGO RSI today: 45.9, below its 50-day and 200-day averages

Not scored

Not in the Quality Score: over 20 years of tests, 2006 to 2026, they added no edge.

RSI 1445.9
Above 30, below 50.
MACD (12, 26, 9)Above signal
Crossed above its signal line 8 sessions ago.
50-day average$13.95
The price is 11.6% below it.
200-day average$12.50
The price is 1.4% below it.
50/200 crossGolden cross
The 50-day crossed above the 200-day on Jun 25.
ADX 1436.1
25 or more, with +DI below -DI.
Support$12.31
Swing low from Jul 14, 0.2% below the price.
Resistance$12.47
Swing high from Oct 23, 1.2% above the price.
52-week high$16.29
From Aug 19, 32.1% above the price.
52-week low$9.39
From Apr 7, 23.8% below the price.
Chart patternFalling channel
Lines over the Sep 1 and Sep 16 highs and under the Jul 14 and Oct 13 lows.
Bollinger Bands (20, 2)Inside
The bands run from $10.87 to $12.64.
Volume1.0x
Against its 20-day average, for the time of day.

The deep dive on ANGO

What it does and how it makes money4 findingsFor Pro members4 findings on what ANGO does and how it makes money, for Pro members
Where it stands4 findingsFor Pro members4 findings on where ANGO stands: its cash, debt, and share count, for Pro members
What changed in its filings1 finding"On April 23, 2026, the Company filed a complaint commencing a patent infringement lawsuit in the United States District Court for the District of Delaware against Endovascular Engineering, Inc. ('E2')." (10-Q for the quarter to Aug 31, 2026)SEC filing · Oct 8, 2026
Who holds and trades it3 findingsFor Pro members3 findings on who holds and trades ANGO, for Pro members

11 more findings on ANGO, each with its source, for Pro membersGet in free →

How ANGO ranks in Medical Devices

ANGO is #73 of 85 by Quality Score.

How ANGO ranks in Medical Devices
1	ATRCAtriCure	7/14	18
2	DXCMDexCom	4/14	18
3	HAEHaemonetics	7/14	17
	ALCAlcon		Open for its score
	ALGNAlign Technology		Open for its score
	AORTArtivion		Open for its score
	ATECAlphatec		Open for its score
73	ANGOAngioDynamics	1/14	-1

When does ANGO report earnings, and what happens after?

Expected to report Wed Jan 6, before the open (in 63 days). Expected.

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What ANGO reported on Oct 8, 2026

The quarter

Sales of $80.9M; a loss of $0.17 a share.

The quarter that ended Aug 31, from the company's press release

The press release The filing on EDGAR

Where the sales came from

Where the quarter's sales came from
Line	Q1 FY27	Q1 FY26
By product
Med Deviceup 1.4%	$41M51%	$40.5M53%

Each quarter's sales and their share of its total. Figures as filed (SEC filing, Oct 8)

5 more lines, for Pro members.

The outlook

No outlook figures read from this release.

The numbers

Market value: $519M; today
Sales: $325M; up 8.2% on the year
Free cash flow: $1.4M; last 12 months

Sales grew 1.9% a year over 5 years, fiscal 2021 to 2026.

Its share count grew 1.6% a year over 5 years.

4 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on ANGO: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.Get in free →

-13.7%+1.8%-20.9%

Apr 2Jul 14Oct 8

Reported	When	Gap	Reaction	5 sessions
Oct 8, 2026Before open	Before open	-6.8%	-20.9%	-22.1%
Jul 14, 2026Before open	Before open	+6.8%	+1.8%	+7.3%
Apr 2, 2026Before open	Before open	-6.0%	-13.7%	-15.5%

ANGO closed higher after 1 of its last 4 reports.

All 4 reports, and ANGO's Quality Score going into each

ANGO sales and profit by year

Sales and profit by year

Sales grew in four of the last six years, to $320M in 2026. It lost money in each of the seven years.

Insiders trading ANGO

ANGO insider trades

2 insiders sold $655K across 3 filings in the last 6 months. No open-⁠market buys on record. The newest:

SellStephen A. Trowbridge$290KEVP and CFOat $12.27 on Oct 29, filed Oct 30

SellStephen A. TrowbridgeEVP and CFO$290Kat $12.27 on Oct 29, filed Oct 30

All 3 insider filings on ANGO from the last six months, for Pro members.Get in free →

All ANGO insider trades

ANGO's officers and directors

Officers and directors with a Form 4 in the last 12 months.

James C. ClemmerPresident and CEO
Stephen A. TrowbridgeEVP and CFO · 2 trades
Warren Nighan Jr.SVP Quality and Regulatory · 1 trade
Chad Thomas CampbellSVP/GM, Vascular Access
Laura PiccininiSVP International
Lawrence T. WeissSVP, Chief Legal Officer
Eileen O'Shea AuenDirector
Howard W. DonnellyDirector

5 more officers and directors file at ANGO. Each page above names the rest.

See insider trades by person

Which ETFs hold ANGO?

In ETFs: ANGO is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About AngioDynamics

AngioDynamics Inc is a dynamic, diversified medical technology company committed to expanding treatment options and improving patient outcomes and quality of life by designing, manufacturing, and selling products and technologies that aid clinicians in the treatment of patients with cardiovascular disease and cancer diagnoses. The company's execution plan is built on R&D, clinical and regulatory pathway expansion, and customer-centric sales performance. The company's product offerings fall within two segments, Med Tech and Med Device. Med Tech includes Auryon and Thrombectomy, while Med Device has Peripheral Products (Interventional Devices), Ports, and Microwave Ablation. Geographically operates in the USA and Other countries; maximum revenue from the USA.

632 employeesLatham, NYangiodynamics.com

What AngioDynamics says it competes with

“We encounter significant competition across our product lines and in each market in which our products are sold.”

From its annual report, SEC filing · Jul 14, 2026

2 more sentences, what it says it does, and its sales by region, for Pro membersGet in free →

ANGO's score card

AngioDynamics (ANGO): Quality Score -1, Poor, #73 of 85 in Medical Devices, with its price, on Breakaway — The picture a link to this page shows when it is shared.

Pro members see every line of every stock's score.

What would turn ANGO's score around: 6 things
3 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawayOct 30Stephen A. Trowbridge sold ANGO$290K at $12.27, filed Oct 30

Alerts are optional.

See ANGO's 14 chart checks

See it live, free for 24 hours. No account. No card. Then keep going with a free account.

Straight Answers

As of Nov 4, 2026: ANGO's Quality Score is -1 (Poor), #73 of 85 in Medical Devices. Insiders sold $655K in the last 6 months (Form 4).

Is ANGO a good stock to buy? What its Quality Score says

ANGO scores -1 today, which Breakaway calls Poor. It is #73 of 85 in Medical Devices by Quality Score, with 1 of 14 chart checks firing. Down 21% on Oct 8, and still 17% under its Oct 7 close. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is ANGO's Quality Score?

ANGO scores -1 today, which Breakaway calls Poor (below zero). That is #73 of 85 in Medical Devices by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ANGO's -1.

Are insiders buying ANGO?

2 insiders sold $655K across 3 filings in the last 6 months. No open-⁠market buys on record. The newest is Stephen A. Trowbridge, EVP and CFO, who sold $290K on Oct 29. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.